AMEX
2.37USD
+0.05 (+2.16%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
191M
P/E
—
EPS
—
Beta
0.01
52W range
1.42-3.19
Day range
2.32–2.39
Open
2.33
Prev close
2.32
Volume
642.1K
Avg volume
727.6K
Dividend
0.00
IPO
1998-05-15
https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-second-quarter-2026-financial-results-and-business-update-on-august-12-2026-302843662.html · 8/5/2026+0.00
https://seekingalpha.com/article/4903948-protalix-biotherapeutics-inc-plx-q1-2026-earnings-call-transcript · 5/13/2026+0.00
https://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-first-quarter-2026-financial-and-business-results-302770790.html · 5/13/2026+0.80
https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-first-quarter-2026-financial-results-and-business-update-on-may-13-2026-302763976.html · 5/6/2026+0.00
https://seekingalpha.com/article/4864805-a-march-decision-that-could-change-protalix-biotherapeutics-outlook · 2/2/2026
https://www.globenewswire.com/news-release/2025/11/03/3179856/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-BioTherapeutics-Seek-Re-examination-from-the-EMA-for-the-Negative-Opinion-for-Elfabrio-pegunigalsidase-alfa-Alternative-Dosing-Regimen-of-E.html · 11/3/2025-0.40
https://www.businesswire.com/news/home/20251031301574/en/PLX-Investors-Have-Opportunity-to-Join-Protalix-BioTherapeutics-Inc.-Fraud-Investigation-with-the-Schall-Law-Firm/ · 11/1/2025-1.00
https://www.defenseworld.net/2025/10/26/protalix-biotherapeutics-nyseplx-vs-invizyne-technologies-nasdaqiztc-critical-survey.html · 10/26/2025+0.00
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
